AI-based drug discovery firm Syntekabio has formed a strategic alliance with large-scale chemical compound producer Enamine to accelerate AI-powered drug development and enhance global market presence.
Under the partnership, Enamine will contribute its synthetic compound library to the collaboration, which Syntekabio will integrate with its AI drug platform DeepMatcher, to discover optimized lead compounds for drug development. This project expects to improve efficiency in drug discovery and further advancements in synthetic drug development.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.